Eugene

[email protected]

LATEST

Eli Lilly and Co Opens Shared Innovation Lab in San Francisco
By

By
Eli Lilly and Company has opened its first shared innovation lab, located in South San Francisco, designed to support the discovery of innovative medicines through collaboration with local biotech companies.…

AbbVie, Harpoon Therapeutics in $820-Million Deal for Immunotherapies
By

By
AbbVie has signed two agreements with Harpoon Therapeutics, a clinical-stage immunotherapy company, in deals worth up to $820 million involving the discovery and development of T cell engagers targeting both…

EMA Holds Stakeholder Workshop on Draft Regulatory Science Strategy
By

By
The European Medicines Agency (EMA) hosted a multi-stakeholder workshop earlier this month (November 18 and 19) on its draft policy document, “Regulatory Science Strategy to 2025.” The draft strategy sets…

Arranta Bio, Delpharm Complete Acquisitions; WuXi AppTec Expands
By

By
The latest news from CDMOs, CMOs, and suppliers featuring news from WuXi AppTec, Lubrizol, Delpharm, and Arranta Bio. Biologics Manufacturing Arranta Bio Acquires Captozyme for Microbiome Development and Clinical Supply…

EMA Moves to Permanent Amsterdam HQ in Light of Brexit
By

By
The European Medicines Agency (EMA) has signed a lease agreement for a newly built facility in Zuidas, Amsterdam, The Netherlands. The EMA moved its headquarters from London to Amsterdam, as…

WuXi Biologics To Build $240-Million Vaccine-Mfg Facility
By

By
WuXi Vaccines, a subsidiary WuXi Biologics focused on contract development and manufacturing services for vaccines, is investing $240 million to build a new vaccine-manufacturing facility in Ireland. This investment follows…

Roche Extends Offer in $4.3-Billion Spark Acquisition
By

By
Roche has extended its tender offer period relating to its pending $4.3-billion acquisition of Spark Therapeutics, a Philadelphia-based gene-therapy company, from November 25, 2019 to December 10, 2019. Roche had…

Novartis To Acquire The Medicines Company for $9.7 Billion
By

By
Novartis has agreed to acquire The Medicines Company, biopharmaceutical company focused on cardiovascular diseases, for $9.7 billion. With the acquisition, Novartis would gain The Medicines Company’s investigational twice-yearly administered therapy…

Fujifilm To Invest $55-Million To Expand Gene-Therapy Development Capabilities
By

By
Fujifilm Diosynth Biotechnologies (FDB), a contract biologics manufacturer, has announced the expansion of its gene-therapy services with the addition of dedicated process and analytical development laboratories. As part of a…

Alkermes Acquires Rodin Therapeutics in $950 Million Deal
By

By
Alkermes, a developer of treatments for central nervous system diseases and oncology, has completed its acquisition of Rodin Therapeutics, a company developing small molecules for treating neurologic diseases, in deal…